 Insulin, Isophane
"Insulin, Isophane" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An intermediate-acting INSULIN preparation with onset time of 2 hours and duration of 24 hours. It is produced by crystallizing ZINC-insulin-PROTAMINES at neutral pH 7. Thus it is called neutral protamine Hagedorn for inventor Hans Christian Hagedorn.
| Descriptor ID |
D007336
|
| MeSH Number(s) |
D06.472.699.587.200.300.200 D12.644.548.586.200.300.200
|
| Concept/Terms |
Insulin, Isophane- Insulin, Isophane
- Isophane Insulin
- Neutral Protamine Hagedorn Insulin
- Protamine Hagedorn Insulin
- Hagedorn Insulin, Protamine
- Isophane Insulin, Regular
- Regular Isophane Insulin
- Insulin, NPH
- NPH Insulin
|
Below are MeSH descriptors whose meaning is more general than "Insulin, Isophane".
Below are MeSH descriptors whose meaning is more specific than "Insulin, Isophane".
This graph shows the total number of publications written about "Insulin, Isophane" by people in this website by year, and whether "Insulin, Isophane" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2013 | 0 | 2 | 2 | | 2017 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Insulin, Isophane" by people in Profiles.
-
Ni K, Hawkins RM, Smyth HL, Seggelke SA, Gibbs J, Lindsay MC, Kaizer LK, Low Wang CC. Safety and Efficacy of Insulins in Critically Ill Patients Receiving Continuous Enteral Nutrition. Endocr Pract. 2024 Apr; 30(4):367-371.
-
Lyon C, Iruku S, Hoss M, DeSanto K, Guthmann R. Is NPH associated with fewer adverse events than analog basal insulin for adults with T2D? J Fam Pract. 2021 05; 70(4):E5-E6.
-
Ji L, Zhang P, Zhu D, Lu J, Guo X, Wu Y, Li X, Ji J, Jia W, Yang W, Zou D, Zhou Z, Gao Y, Garg SK, Pan C, Weng J, Paul SK. Comparative effectiveness and safety of different basal insulins in a real-world setting. Diabetes Obes Metab. 2017 08; 19(8):1116-1126.
-
Shah VN, Moser EG, Blau A, Dhingra M, Garg SK. The future of basal insulin. Diabetes Technol Ther. 2013 Sep; 15(9):727-32.
-
Low Wang CC, Draznin B. Practical approach to management of inpatient hyperglycemia in select patient populations. Hosp Pract (1995). 2013 Apr; 41(2):45-53.
-
Seggelke SA, Gibbs J, Draznin B. Pilot study of using neutral protamine Hagedorn insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes. J Hosp Med. 2011 Mar; 6(3):175-6.
-
Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review. Diabetes Technol Ther. 2010 Jan; 12(1):11-24.
-
Garg SK, Naik RG. Long-acting insulin analogs versus human insulins. Diabetes Technol Ther. 2008 Oct; 10(5):331-2.
-
Garg SK, Paul JM, Karsten JI, Menditto L, Gottlieb PA. Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol Ther. 2004 Oct; 6(5):589-95.
-
Chase HP, Dixon B, Pearson J, Fiallo-Scharer R, Walravens P, Klingensmith G, Rewers M, Garg SK. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr. 2003 Dec; 143(6):737-40.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|